AlphAIalphai — Financial news for AI agents
financialcontent.comAUG 63 min read$CLMT

Calumet (CLMT) Q2 Earnings Report Preview: What To Look For

Calumet (CLMT) is set to report Q2 results. Last quarter, it posted revenue of $1.03 billion, up 3.6% year on year, beating revenue expectations, and it beat EPS but missed EBITDA. For Q2, analysts expect revenue growth of 6.6% year on year. CLMT is up 4.2% over the past month, with an average price target of $39.60 versus $40.42.

Original reporting
financialcontent.com
Published Aug 6, 2026, 11:00 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 11:56 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Calumet (CLMT) Q2 Earnings Report Preview: What To Look For — source image
Source · financialcontent.com
Decision brief

The 30-second read

$CLMTNeutralLow
01

Why it matters

The main tradable element is the earnings timing plus consensus revenue growth and the fact that analysts reconfirmed estimates recently. However, the piece does not disclose new guidance, filings, or a fresh operational development.

02

Market read

Earnings preview for CLMT with consensus revenue growth and recent estimate behavior, plus peer results as a loose read-through.

03

What to watch

The preview highlights a prior EBITDA miss but does not specify what changed in Q2; without margin, guidance, or cash-flow details, the setup may be too generic for directional conviction.

Relevance 4/10Novelty 3/10Timing: tomorrow morning earnings release

Background

Calumet is a specialty products refiner reporting Q2 results tomorrow morning. The article recalls last quarter’s revenue beat and EPS beat alongside an EBITDA miss, then summarizes current consensus and peer read-through.

Company-level read

Ticker impact

$CLMTNeutralMedium confidence
Context

Calumet (CLMT) is set to report Q2 results tomorrow, with the article citing revenue growth expectations and recent estimate reconfirmations.

Expected impact

Near-term volatility likely around the earnings release, but direction is uncertain because the article provides no new guidance or datapoint beyond expectations.

Evidence & confidence

The newest concrete facts are consensus revenue growth (6.6% YoY) and that analysts reconfirmed estimates over 30 days; there is no fresh company-specific disclosure like guidance, contract, or regulatory action.

Market effects

Sector

Infrastructure and energy refiners are referenced via peer results, but the article does not provide a new sector catalyst.

Regional

None stated.

Global

None stated.

Counterpoint

What could challenge this read

Because the article emphasizes that Calumet rarely misses revenue estimates, traders may already be positioned for a revenue beat, making EBITDA or margin surprises the main swing factor.

Key entities

  • company
    Calumet

    Subject of the preview, scheduled to report Q2 results tomorrow morning.

  • company
    Expand Energy

    Peer cited for Q2 revenue decline and a large beat versus expectations.

  • company
    Kinder Morgan

    Peer cited for Q2 revenue growth and a modest beat versus expectations.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 7
$CLMTMed

Why Calumet Stock Flopped on Friday

Calumet (CLMT) shares fell about 6% on Friday after its Q2 earnings showed a surprise net loss. Revenue rose to just under $1.45B, up about 41% YoY, but adjusted net loss was $95.9M, or $1.09/share, versus a year-ago deficit of $147.9M. Analysts expected profit of $0.17/share. Long-term debt exceeded $2.2B.

fool.com4 min
AUG 7
$CLMTMed

Calumet (NASDAQ:CLMT) Surprises With Strong Q2 CY2026

Calumet (NASDAQ:CLMT) reported Q2 CY2026 results. Revenue rose 40.8% year on year to $1.45 billion, beating Wall Street estimates by 32% (according to the article). Adjusted EBITDA exceeded consensus by 78.2%, with margin rising to 12.1%. Free cash flow was $99.35 million, turning positive after a year-ago loss.

financialcontent.com6 min
JUL 9
$CLMTMed

Why Calumet Stock Was a Major Winner on Wednesday

Calumet (CLMT) shares rose more than 4% after the company said two wholly owned subsidiaries will redeem $100 million of senior notes due 2028, paying about 102.4% of par. Calumet also noted it reduced borrowings on its revolving credit facility in Q2, as part of a deleveraging plan.

fool.com4 min
AUG 8
$DTMedAI 8/10

Dynatrace Springs on Q1 Figures

Dynatrace (NYSE: DT) reported Q1 FY2027 results for the quarter ended June 30, 2026. Total ARR was $2,136 million, up 17%. Total revenue rose to $555 million, up 16%. Subscription revenue was $530 million. GAAP operating income was $71 million and non-GAAP $162 million. CEO Rick McConnell cited 41% organic net new ARR growth and accelerating TTM growth.

baystreet.ca2 min
AUG 8
$DBXMed

Dropbox Shares Decline Despite Earnings Beat as Revenue Growth Disappoints

Dropbox (DBX) shares fell about 5% premarket to around $32.80 after Q2 2026 results. The company reported adjusted EPS of $0.75 vs $0.74 expected and revenue of $631.5M vs about $627M, but revenue rose only 0.9% year over year. Non-GAAP operating margin improved to 39.7%. Paying users reached 18.19M. William Blair upgraded to Market Perform, while consensus remains Sell.

yahoo.com4 min